Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Gross Profit for the quarter ending March 31, 2024: USD -7.00 K

Iterum Therapeutics PLC Gross Profit is USD -7.00 K for the quarter ending March 31, 2024, a 98.39% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Iterum Therapeutics PLC Gross Profit for the quarter ending March 31, 2023 was USD -436.00 K.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email